Endothelial dysfunction in diabetes

British Journal of Pharmacology - Tập 130 Số 5 - Trang 963-974 - 2000
An S. De Vriese1, Tony J. Verbeuren, Johan Van de Voorde, Norbert Lameire, P M Vanhoutte
1Renal Unit, Ghent University, Ghent, Belgium.

Tóm tắt

Endothelial dysfunction plays a key role in the pathogenesis of diabetic vascular disease. The endothelium controls the tone of the underlying vascular smooth muscle through the production of vasodilator mediators. The endothelium‐derived relaxing factors (EDRF) comprise nitric oxide (NO), prostacyclin, and a still elusive endothelium‐derived hyperpolarizing factor (EDHF). Impaired endothelium‐dependent vasodilation has been demonstrated in various vascular beds of different animal models of diabetes and in humans with type 1 and 2 diabetes. Several mechanisms of endothelial dysfunction have been reported, including impaired signal transduction or substrate availibility, impaired release of EDRF, increased destruction of EDRF, enhanced release of endothelium‐derived constricting factors and decreased sensitivity of the vascular smooth muscle to EDRF. The principal mediators of hyperglycaemia‐induced endothelial dysfunction may be activation of protein kinase C, increased activity of the polyol pathway, non‐enzymatic glycation and oxidative stress. Correction of these pathways, as well as administration of ACE inhibitors and folate, has been shown to improve endothelium‐dependent vasodilation in diabetes. Since the mechanisms of endothelial dysfunction appear to differ according to the diabetic model and the vascular bed under study, it is important to select clinically relevant models for future research of endothelial dysfunction.

British Journal of Pharmacology(2000)130, 963–974; doi:10.1038/sj.bjp.0703393

Từ khóa


Tài liệu tham khảo

10.1016/S0735-1097(99)00259-4

10.1007/PL00005289

10.2337/diacare.22.9.1536

10.2337/diabetes.48.1.1

10.1111/j.2042-7158.1988.tb07009.x

10.1097/00005344-199504000-00021

BOHLEN H.G., 1993, Topical hyperglycemia rapidly suppresses EDRF‐mediated vasodilation of normal rat arterioles, Am. J. Physiol., 265, H219

BOHLEN H.G., 1995, Endothelium‐dependent vasodilation is preserved in non‐insulin‐dependent Zucker fatty diabetic rats, Am. J. Physiol., 268, H2366

10.1172/JCI115014

10.1172/JCI116149

10.1007/BF02221675

CERIELLO A., 1999, Hyperglycemia: the bridge between non‐enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications, Diabetes Nutr. Metab., 12, 42

10.1016/0735-1097(96)82380-1

10.1055/s-2007-978831

10.1016/1056-8727(95)80012-4

10.2337/diabetes.47.6.918

DAI F., 1993, Diabetes‐induced endothelial dysfunction in streptozotocin‐treated rats: role of prostaglandin endoperoxides and free radicals, J. Am. Soc. Nephrol., 4, 1327, 10.1681/ASN.V461327

DE VRIESE A., 1999, Impaired endothelium‐derived hyperpolarizing factormediated renal vasodilatory response in diabetes: restoration with folate, J. Am. Soc. Nephrol., 10, 394A

DIEDERICH D., 1994, Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals, Am. J. Physiol., 266, H1153

10.1111/j.1476-5381.1988.tb11548.x

10.2337/diacare.21.2.271

10.1016/0306-3623(94)00159-K

10.1006/jmcc.1998.0840

10.1111/j.1476-5381.1983.tb10016.x

FRIEDMAN E.A., 1999, Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications, Diabetes Care, 22, B65

10.1038/sj.bjp.0701258

FULTON D., 1996, Cytochrome P450 arachidonate metabolites: deficit in diabetes mellitus, FASEB J., 9, A113

10.1096/fasebj.3.9.2545495

10.1056/NEJM197304192881609

10.1046/j.1464-5491.1999.00049.x

10.1093/cvr/22.8.537

10.2337/diacare.19.3.257

HATTORI Y., 1991, Superoxide dismutase recovers altered endothelium‐dependent relaxation in diabetic rat aorta, Am. J. Physiol., 261, H1086

10.1111/j.1476-5381.1987.tb10282.x

10.1111/j.1476-5381.1995.tb15132.x

HILL M.A., 1994, Active and passive mechanical properties of isolated arterioles from STZ‐induced diabetic rats. Effect of aminoguanidine treatment, Diabetes, 43, 1450, 10.2337/diab.43.12.1450

10.1172/JCI116716

10.1161/01.CIR.88.6.2510

10.2337/diabetes.37.3.292

KATUSIC Z.S., 1989, Superoxide anion is an endothelium‐derived contracting factor, Am. J. Physiol., 257, H33

10.1177/1358863X9600100303

10.1007/BF00400609

10.1111/j.1476-5381.1991.tb09793.x

10.1016/S0008-6363(97)00050-3

10.1164/ajrccm/136.2.474

10.2337/diabetes.47.6.859

10.1152/ajpendo.1995.269.2.E239

10.1161/01.ATV.16.5.705

10.1161/01.RES.69.5.1259

10.1016/S0008-6363(97)00015-1

10.1042/cs0890183

10.1097/00005344-199607000-00010

10.1016/S0006-8993(97)00282-5

MAYHAN W.G., 1993, Responses of cerebral arterioles in diabetic rats to activation of ATP‐sensitive potassium channels, Am. J. Physiol., 265, H152

MAYHAN W.G., 1995, Acute effects of glucose on reactivity of cerebral microcirculation: role of activation of protein kinase C, Am. J. Physiol., 269, H1297

10.1152/ajpheart.1998.274.6.H1895

10.1159/000179217

MAYHAN W.G., 1991, Mechanisms of impaired responses of cerebral arterioles during diabetes mellitus, Am. J. Physiol., 260, H319

10.1046/j.1464-5491.1999.00021.x

10.1042/cs0870031

10.1007/BF00429099

10.1007/BF00399090

10.1046/j.1523-1755.1999.00302.x

10.1016/S0165-6147(97)90633-7

10.1111/j.1476-5381.1989.tb12555.x

10.1016/S0735-1097(98)00099-0

NITENBERG A., 1993, Impairment of coronary vascular reserve and ACh‐induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function, Diabetes, 42, 1017, 10.2337/diab.42.7.1017

10.1016/S0735-1097(99)00065-0

10.1172/JCI119580

10.1111/j.1476-5381.1994.tb17028.x

10.1016/0014-2999(86)90013-0

10.1007/s001250050884

10.1007/s001250050883

10.1097/00001756-199401120-00011

PERICO N., 1999, Nephropathy in type 2 diabetes, 47, 10.1093/oso/9780192629456.003.0004

10.2337/diab.46.2.S82

10.1016/S0039-6060(98)70233-8

PIEPER G.M., 1988, Oxygen free radicals abolish endothelium‐dependent relaxation in diabetic aorta, Am. J. Physiol., 255, H825

10.1016/S0008-6363(96)00237-4

10.1152/ajpheart.1992.263.3.H676

10.1016/0024-3205(95)02360-7

10.1097/00005344-199503000-00008

10.1097/00005344-199807000-00016

QUILLEY J., 1996, NO‐independent coronary vasodilation to bradykinin in diabetes, Hypertension, 28, P178

10.1016/0168-8227(96)01242-9

10.1152/ajpcell.1986.250.3.C406

SAKAMOTO S., 1998, Effect of exercise training and food restriction on endothelium‐dependent relaxation in the Otsuka Long‐Evans Tokushima Fatty rat, a model of spontaneous NIDDM, Diabetes, 47, 82, 10.2337/diab.47.1.82

10.1161/01.RES.84.5.489

10.1161/01.CIR.89.4.1776

10.2337/diabetes.42.9.1246

SMITS P., 1993, Endothelium‐dependent vascular relaxation in patients with type I diabetes, Diabetes, 42, 148, 10.2337/diab.42.1.148

10.1113/expphysiol.1997.sp004038

10.1042/cs0880519

10.1111/j.1476-5381.1992.tb12757.x

10.1111/j.1476-5381.1994.tb14020.x

10.1111/j.1476-5381.1994.tb14021.x

10.1172/JCI115179

10.1172/JCI114521

10.1152/ajpheart.1992.263.2.H321

TESFAMARIAM B., 1989, Contraction of diabetic rabbit aorta caused by endothelium‐derived PGH2‐TxA2, Am. J. Physiol., 257, H1327

10.1097/00005344-199302000-00004

THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP/EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS RESEARCH GROUP(2000).Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.N. Eng. J. Med. 342 381–389.

TILTON R.G., 1993, Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end‐product formation, Diabetes, 42, 221, 10.2337/diab.42.2.221

10.1172/JCI118394

10.1042/CS19980382

10.1016/S0002-9149(99)80496-2

10.1161/01.CIR.100.4.335

10.1016/0024-3205(87)90265-7

WANG Y., 1993, Attenuated glomerular cGMP production and renal vasodilation in streptozotocin‐induced diabetic rats, Am. J. Physiol., 264, R952

10.1159/000138197

10.1016/0735-1097(95)00522-6

10.1042/bj2450243

YAN S.D., 1994, Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins, J. Cell. Biol., 269, 9889

10.2337/diacare.18.7.975

ZENON G.J., 1990, Potential use of aldose reductase inhibitors to prevent diabetic complications, Clin. Pharm., 9, 446